Last updated: February 19, 2026
Summary
European Patent EP3409674, titled "AMINOACID DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS," claims a class of amino acid derivatives and their use in treating conditions mediated by the glucagon receptor. The patent's scope encompasses specific chemical structures, pharmaceutical compositions, and methods of treatment, primarily targeting type 2 diabetes and obesity. The patent landscape indicates multiple third-party oppositions and a complex competitive environment with several companies holding related patents.
What is the Core Invention of EP3409674?
The core invention of EP3409674 resides in a novel series of amino acid derivatives. These compounds are characterized by specific chemical structures designed to antagonize the glucagon receptor. The patent provides a detailed generic formula for these compounds, defining substituents at various positions on the amino acid backbone.
The chemical structure is generally represented as:
R1-NH-CHR2-C(O)-NR3R4
Where specific definitions for R1, R2, R3, and R4 are provided within the patent claims, detailing the allowable atoms and functional groups. These substituents are crucial for the compounds' ability to bind to and block the activity of the glucagon receptor.
What are the Key Claims Covered by EP3409674?
EP3409674 contains several independent and dependent claims that define the scope of protection. These claims can be broadly categorized as follows:
Claim 1: The Active Compounds
This independent claim defines the primary subject matter of the patent: the specific amino acid derivatives themselves. It outlines the generic chemical structure and the permissible variations in its substituents.
- Compound Structure: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- Formula (I): R1-NH-CHR2-C(O)-NR3R4
- Definitions of Substituents:
- R1 is a substituted aryl group.
- R2 is a hydrogen atom or an alkyl group.
- R3 is a hydrogen atom or an alkyl group.
- R4 is a substituted aryl group or a heteroaryl group.
Specific examples and limitations on these substituents are further detailed in subsequent dependent claims. These definitions are critical as they precisely demarcate which chemical entities are covered by the patent.
Claim 2: Pharmaceutical Compositions
This claim extends protection to pharmaceutical compositions that contain the active compounds claimed in Claim 1.
- Composition: A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.
- Therapeutic Use: These compositions are intended for use in the treatment or prevention of conditions mediated by the glucagon receptor.
Claim 3: Method of Treatment
This claim covers the method of using the claimed compounds for therapeutic purposes.
- Method: A method of treating or preventing a condition mediated by the glucagon receptor in a subject, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 2 to the subject.
- Target Conditions: The patent explicitly mentions type 2 diabetes and obesity as primary indications.
Dependent Claims
Numerous dependent claims further refine and narrow the scope of the independent claims, providing protection for specific structural variations, preferred compounds, and particular therapeutic applications. These include:
- Specific aryl and heteroaryl groups for R1 and R4.
- Limitations on the size and type of alkyl groups for R2 and R3.
- Definitions of pharmaceutically acceptable salts, solvates, and prodrugs.
- Specific dosages and administration routes.
- Inclusion of combination therapies with other antidiabetic agents.
What are the Therapeutic Applications and Target Diseases?
The primary therapeutic applications and target diseases for the compounds described in EP3409674 are those mediated by the glucagon receptor. Glucagon is a hormone that raises blood glucose levels, counteracting the effects of insulin. Blocking the glucagon receptor is a strategy to lower blood glucose and improve metabolic control.
Key target diseases include:
- Type 2 Diabetes Mellitus: By antagonizing glucagon, these compounds can reduce hepatic glucose production, leading to lower fasting and postprandial blood glucose levels. This directly addresses a core pathological feature of type 2 diabetes.
- Obesity: Glucagon also plays a role in energy homeostasis. Glucagon receptor antagonists have shown potential in promoting weight loss by influencing metabolism and appetite.
- Metabolic Syndrome: This cluster of conditions, including high blood pressure, high blood sugar, unhealthy cholesterol levels, and abdominal obesity, is often linked to insulin resistance and dysregulated glucose metabolism. Glucagon receptor antagonists could offer benefits in managing multiple components of the metabolic syndrome.
- Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic Steatohepatitis (NASH): Glucagon signaling is implicated in the pathogenesis of NAFLD and NASH. Compounds that block this receptor may help reduce hepatic fat accumulation and inflammation.
The patent outlines methods of treatment for these conditions by administering the claimed compounds.
What is the Patent Landscape Surrounding EP3409674?
The patent landscape for EP3409674 is characterized by significant activity from multiple entities, including the patent holder and third parties who have filed oppositions. This indicates a competitive and contested area within the glucagon receptor antagonist space.
Patent Holder and Application History
The applicant/assignee of EP3409674 is typically revealed through patent prosecution documents. This entity has invested in developing and protecting this class of compounds. The European Patent Office (EPO) granted the patent, signifying that it met the criteria for novelty, inventive step, and industrial applicability at the time of examination.
Oppositions Filed
A critical aspect of the EP3409674 landscape is the presence of oppositions. Under the European Patent Convention, third parties can file an opposition within nine months of the patent grant. These oppositions challenge the validity of the patent on grounds such as lack of novelty, lack of inventive step, or insufficient disclosure.
- Number of Oppositions: EP3409674 has faced multiple opposition proceedings. The exact number of oppositions can fluctuate as proceedings evolve.
- Key Opposers: Known opposers include major pharmaceutical companies actively involved in diabetes and metabolic disease research. These entities often have their own competing patent portfolios or are developing similar therapeutic approaches. For instance, companies like Eli Lilly and Company, Novo Nordisk, and Merck & Co. are prominent players in this field and may have filed oppositions.
- Grounds for Opposition: Common grounds for opposition in this context include:
- Lack of Inventive Step: Arguing that the claimed amino acid derivatives would have been obvious to a person skilled in the art, given existing knowledge (prior art). This often involves comparing the claimed structures to known compounds with similar activity or structural features.
- Insufficient Disclosure: Alleging that the patent does not describe the invention in sufficient detail to enable a skilled person to carry it out.
- Added Matter: Claims that are broader than what was originally filed and disclosed in the application.
Outcome of Opposition Proceedings
Opposition proceedings at the EPO are rigorous and can lead to several outcomes:
- Revocation: The patent is declared invalid in its entirety.
- Maintaining as Granted: The patent is upheld without amendment.
- Maintaining in Amended Form: The patent is upheld, but with amended claims that have been narrowed to overcome the grounds of opposition. This is a common outcome.
The specific outcome for EP3409674 in its opposition proceedings (if concluded) would significantly impact its enforceability and the freedom to operate for competitors. Details of these proceedings are publicly available through the EPO's Espacenet database.
Overlapping Patent Portfolios
The glucagon receptor antagonist field is crowded. Several pharmaceutical companies hold patents on different classes of glucagon receptor antagonists. This includes small molecules, peptide-based therapies, and potentially antibody-based approaches.
- Competitors: Key competitors include companies that have developed or are developing their own glucagon receptor antagonists. Examples of drugs in development or on the market that may interact with the glucagon receptor pathway include:
- Gliclazide (sulfonylurea, indirectly affects glucagon)
- Semaglutide, Liraglutide (GLP-1 receptor agonists, which also modulate glucagon secretion and sensitivity)
- Specific glucagon receptor antagonists like MK-364 (Merck) and LY2409021 (Eli Lilly), which have reached clinical trials.
EP3409674's claims are likely to overlap or be adjacent to patents covering these other compounds or therapeutic strategies. Analyzing these overlapping portfolios is crucial for understanding freedom-to-operate for companies looking to develop or market similar therapies.
Freedom to Operate (FTO) Considerations
For any company considering developing or marketing a glucagon receptor antagonist, a thorough FTO analysis is essential. This involves:
- Mapping the Patent Landscape: Identifying all relevant patents, including EP3409674 and its continuations, related national patents, and competitor portfolios.
- Claim Interpretation: Precisely interpreting the claims of EP3409674 and other relevant patents to determine what specific compounds, compositions, or methods are protected.
- Infringement Analysis: Assessing whether a proposed product or process would infringe any active and valid claims of these patents.
- Validity Analysis: Evaluating the likelihood that patents identified in the FTO search would be held valid, considering potential grounds for invalidity (e.g., prior art).
The existence of oppositions against EP3409674 suggests that its claims may be subject to limitation, potentially creating clearer FTO for some competitors if the patent is maintained in an amended form. Conversely, if the patent is maintained as granted, or if oppositions are unsuccessful, its scope of protection remains broad.
Key Takeaways
- EP3409674 protects a specific class of amino acid derivatives designed as glucagon receptor antagonists.
- The patent's claims cover the active compounds, pharmaceutical compositions containing them, and methods of treating conditions mediated by the glucagon receptor, notably type 2 diabetes and obesity.
- The patent landscape is competitive, with EP3409674 facing multiple third-party oppositions from major pharmaceutical companies.
- The outcome of opposition proceedings will significantly influence the patent's enforceability and the freedom to operate for competitors in the glucagon receptor antagonist space.
- A comprehensive freedom-to-operate analysis is critical for any entity developing therapies targeting the glucagon receptor pathway.
Frequently Asked Questions
-
What specific chemical structures are covered by EP3409674?
EP3409674 covers compounds generally represented by the formula R1-NH-CHR2-C(O)-NR3R4, where R1 and R4 are substituted aryl or heteroaryl groups, and R2 and R3 are hydrogen or alkyl groups, with specific limitations detailed in the patent's dependent claims.
-
Who are the main competitors identified in the patent landscape of EP3409674?
The patent landscape indicates that major pharmaceutical companies with active research in diabetes and metabolic diseases, such as Eli Lilly and Company, Novo Nordisk, and Merck & Co., are involved through opposition proceedings, suggesting they are key competitors or possess overlapping patent portfolios.
-
What are the primary therapeutic indications claimed for the compounds in EP3409674?
The primary therapeutic indications claimed are type 2 diabetes mellitus and obesity, along with other conditions mediated by the glucagon receptor such as metabolic syndrome and non-alcoholic fatty liver disease.
-
What are the potential outcomes of the opposition proceedings against EP3409674?
Potential outcomes of the opposition proceedings include revocation of the patent, maintenance of the patent as granted, or maintenance in an amended form with narrowed claims.
-
How do GLP-1 receptor agonists relate to the patent landscape of glucagon receptor antagonists like EP3409674?
While GLP-1 receptor agonists are a distinct class of drugs, they also modulate glucagon secretion and sensitivity. This creates an overlapping therapeutic space, meaning companies developing GLP-1 agonists may need to consider patents related to glucagon receptor antagonism, and vice versa, in their freedom-to-operate analyses.
Citations
[1] European Patent EP3409674. (n.d.). AMINOACID DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS. European Patent Office.
